Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Orexigen Therapeutics Enters into Agreement with Merck KGaA 12
Orexigen Therapeutics Enters into Distribution Agreement with CHEPLAPHARM Arzneimittel 13
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 14
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 15
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 16
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 17
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 18
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 19
Orexigen Therapeutics Ireland Enters into Distribution Agreement with Kwang Dong Pharmaceutical 20
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 21
Licensing Agreements 22
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 22
Equity Offering 23
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 23
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 24
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 25
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 26
Debt Offering 28
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 28
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 29
Acquisition 30
Orexigen Therapeutics Plans to Sell Itself 30
Orexigen Therapeutics Inc – Key Competitors 31
Orexigen Therapeutics Inc – Key Employees 32
Orexigen Therapeutics Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 13, 2017: Orexigen Therapeutics Announces Third Quarter 2017 Financial Results 34
Aug 08, 2017: Orexigen Therapeutics Announces Second Quarter 2017 Financial Results 35
May 11, 2017: Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2017 36
Mar 28, 2017: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 37
Nov 03, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2016 39
Aug 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2016 41
May 04, 2016: Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016 42
Feb 26, 2016: Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015 43
Corporate Communications 45
May 23, 2016: Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes 45
Product News 46
11/16/2016: Orexigen Announces Presentation of Data for OREX-1019, a Preclinical Candidate for the Treatment and Management of Drug Addiction 46
06/08/2016: Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO 47
05/27/2016: Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board 49
05/16/2017: Orexigen Announces Activities at European Congress on Obesity 2017 51
05/03/2016: Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development 52
05/02/2016: Orexigen Announces South Korean Approval of Contrave (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients 54
01/25/2017: Orexigen Therapeutics Announces Spanish Launch of Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Partnership with Laboratorios Farmace´uticos Rovi 55
01/05/2017: Orexigen Therapeutics Provides Update On Contrave At 35th Annual J.P. Morgan Healthcare Conference 56
Product Approvals 58
Apr 25, 2017: Orexigen Therapeutics Announces New Drug Submission for Contrave in Canada 58
Clinical Trials 59
Jan 06, 2017: Orexigen Therapeutics Announces Publication of Contrave Real-World Study Results in “Obesity” 59
Other Significant Developments 60
Jan 11, 2016: Orexigen announces 2016 financial outlook and key priorities 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Orexigen Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Orexigen Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Orexigen Therapeutics Enters into Agreement with Merck KGaA 12
Orexigen Therapeutics Enters into Distribution Agreement with CHEPLAPHARM Arzneimittel 13
Orexigen Therapeutics Enters into Distribution Agreement with Navamedic 14
Orexigen Therapeutics Enters into Distribution Agreement with Bruno Farmaceutici for Mysimba 15
Orexigen Therapeutics Enters into Distribution Agreement with Consilient Health for Mysimba 16
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma 17
Orexigen Therapeutics Enters into Distribution Agreement with Valeant for Contrave 18
Orexigen Therapeutics Enters into Distribution Agreement with Laboratorios Farmaceuticos Rovi 19
Orexigen Therapeutics Ireland Enters into Distribution Agreement with Kwang Dong Pharmaceutical 20
Orexigen Therapeutics Enters into Distribution Agreement with Valeant Pharma for Mysimba 21
Orexigen Therapeutics Enters into Licensing Agreement with University of Bath 22
Orexigen Therapeutics Plans to Raise up to USD20 Million in Public Offering of Shares 23
Orexigen Therapeutics Raises USD60 Million in Private Placement of Shares 24
Orexigen Therapeutics Completes Public Offering Of Common Stock For US$61 Million 25
Orexigen Therapeutics Completes Public Offering Of Units For US$90 Million 26
Orexigen Therapeutics Raises USD165 Million in Private Placement of Notes Due 2020 28
Orexigen Therapeutics Completes Private Placement Of Notes Due 2020 For US$115 Million 29
Orexigen Therapeutics Plans to Sell Itself 30
Orexigen Therapeutics Inc, Key Competitors 31
Orexigen Therapeutics Inc, Key Employees 32
Orexigen Therapeutics Inc, Subsidiaries 33
【免責事項】
http://www.globalresearch.jp/disclaimer